Erratum: Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies (Nature Medicine (2016) DOI: 10.1038/nm.4201);Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies

Nature Medicine

Volumn 22, Issue 12, 2016, Pages 1439-1447

  Khurana, Surender ^a   Fuentes, Sandra ^a   Coyle, Elizabeth M ^a   Ravichandran, Supriya ^a   Davey, Richard T ^b   Beigel, John H ^c  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN; VIRUS VECTOR; GLYCOPROTEIN; IMMUNOGLOBULIN M; LIVE VACCINE; VIRUS ANTIBODY;

ADULT; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; EBOLA HEMORRHAGIC FEVER; FEMALE; HUMAN; MALE; NORMAL HUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; VACCINATION; VESICULOVIRUS; VIRUS NEUTRALIZATION; EBOLAVIRUS; IMMUNOLOGY; VACCINE IMMUNOGENICITY; VESICULAR STOMATITIS INDIANA VIRUS;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; EBOLA VACCINES; EBOLAVIRUS; EPITOPES; FEMALE; GLYCOPROTEINS; HEALTHY VOLUNTEERS; HUMANS; IMMUNOGENICITY, VACCINE; IMMUNOGLOBULIN M; MALE; VACCINES, ATTENUATED; VESICULAR STOMATITIS INDIANA VIRUS;

EID: 84992724541     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0217-264c     Document Type: Erratum

References (40)

1. Centers for Disease Control and Prevention. 2014 Ebola outbreak in West Africa-case counts. Centers for Disease Control and Prevention http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/case-counts.html (2016).
2. Kanapathipillai, R. et al. Ebola vaccine-an urgent international priority. N. Engl. J. Med. 371, 2249-2251 (2014).
3. Henao-Restrepo, A.M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857-866 (2015).
4. Krause, P.R. Interim results from a phase 3 Ebola vaccine study in Guinea. Lancet 386, 831-833 (2015).
5. Marzi, A., Feldmann, F., Geisbert, T.W., Feldmann, H., Safronetz, D. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses. Emerg. Infect. Dis. 21, 305-307 (2015).
6. Marzi, A. et al. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 349, 739-742 (2015).
7. Rampling, T. et al. A monovalent chimpanzee adenovirus Ebola vaccine-preliminary report. N. Engl. J. Med. 374, 1635-1646 (2016).
8. Regules, J.A. et al. A recombinant vesicular stomatitis virus Ebola vaccine-preliminary report. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1414216 (2015).
9. Tapia, M.D. et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults., boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial., a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis. 16, 31-42 (2016).
10. Jones, S.M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786-790 (2005).
11. Dye, J.M. et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl. Acad. Sci. USA 109, 5034-5039 (2012).
12. Holtsberg, F.W. et al. Pan-ebolavirus and pan-filovirus mouse monoclonal antibodies: protection against Ebola and Sudan viruses. J. Virol. 90, 266-278 (2016).
13. Marzi, A. et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl. Acad. Sci. USA 110, 1893-1898 (2013).
14. Wilson, J.A. et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287, 1664-1666 (2000).
15. Matassov, D. et al. Vaccination with a highly attenuated recombinant vesicular stomatitis virus vector protects against challenge with a lethal dose of Ebola virus. J. Infect. Dis. 212 (Suppl. 2), S443-S451 (2015).
16. Blaney, J.E. et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog. 9, e1003389 (2013).
17. Wong, G. et al. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci. Transl. Med. 4, 158ra146 (2012).
18. Ruibal, P. et al. Unique human immune signature of Ebola virus disease in Guinea. Nature 533, 100-104 (2016).
19. Cohen, J., Enserink, M. Clinical trials. Ebola vaccines face daunting path to approval. Science 349, 1272-1273 (2015).
20. Krause, P.R., Cavaleri, M., Coleman, G., Gruber, M.F. Approaches to demonstration of Ebola virus vaccine efficacy. Lancet Infect. Dis. 15, 627-629 (2015).
21. Khurana, S. et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2, 15ra5 (2010).
22. Khurana, S. et al. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med. 6, e1000049 (2009).
23. Khurana, S. et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3, 85ra48 (2011).
24. Flyak, A.I. et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural Ebolavirus infection. Cell 164, 392-405 (2016).
25. Davidson, E. et al. Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb., MB-003 cocktail antibodies. J. Virol. 89, 10982-10992 (2015).
26. Murin, C.D. et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc. Natl. Acad. Sci. USA 111, 17182-17187 (2014).
27. Lee, J.E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177-182 (2008).
28. Yang, J. et al. The I-TASSER Suite: protein structure and function prediction. Nat. Methods 12, 7-8 (2015).
29. Geisbert, T.W. et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of Ebola virus. J. Virol. 83, 7296-7304 (2009).
30. Chung, K.Y. et al. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus-like particle vaccine that correlate with virus neutralization in humans. Vaccine 33, 3953-3962 (2015).
31. Nicholson, K.G. et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357, 1937-1943 (2001).
32. Jackson, L.A. et al. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial. J. Am. Med. Assoc. 314, 237-246 (2015).
33. Mulligan, M.J. et al. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. J. Am. Med. Assoc. 312, 1409-1419 (2014).
34. Fuentes, S., Coyle, E.M., Beeler, J., Golding, H., Khurana, S. Antigenic fingerprinting following primary RSV infection in young children identifies novel antigenic sites and reveals unlinked evolution of human antibody repertoires to fusion and attachment glycoproteins. PLoS Pathog. 12, e1005554 (2016).
35. Gitlin, A.D. et al. Humoral immunity. T cell help controls the speed of the cell cycle in germinal center B cells. Science 349, 643-646 (2015).
36. McHeyzer-Williams, L.J., Milpied, P.J., Okitsu, S.L., McHeyzer-Williams, M.G. Class-switched memory B cells remodel BCRs within secondary germinal centers. Nat. Immunol. 16, 296-305 (2015).
37. Khurana, S. et al. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J. Infect. Dis. 208, 413-417 (2013).
38. Ledgerwood, J.E. et al. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J. Infect. Dis. 208, 418-422 (2013).
39. Halliley, J.L. et al. High-affinity H7 head and stalk domain-specific antibody responses to an inactivated influenza H7N7 vaccine after priming with live attenuated influenza vaccine. J. Infect. Dis. 212, 1270-1278 (2015).
40. Talaat, K.R. et al. A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J. Infect. Dis. 209, 1860-1869 (2014).